Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy

Immunosuppressive therapy increases the risk of pneumococcal disease. This risk can be mitigated by pneumococcal vaccination. The objective of this study was to investigate the immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13), followed by the 23-valent pneumococcal polysacchari...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia Garrido, Hannah M., Vollaard, Albert, D’Haens, Geert R., Spuls, Phyllis I., Bemelman, Frederike J., Tanck, Michael W., de Bree, Godelieve J., Meek, Bob, Grobusch, Martin P., Goorhuis, Abraham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146363/
https://www.ncbi.nlm.nih.gov/pubmed/35632551
http://dx.doi.org/10.3390/vaccines10050795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146363/
https://www.ncbi.nlm.nih.gov/pubmed/35632551
http://dx.doi.org/10.3390/vaccines10050795

Ejemplares similares